Skip to content
Advertisement

Guardant Health’s GuardantINFORM platform combines de-identified longitudinal clinical and genomic data from more than 207,000 patients tested with its Guardant360 liquid-biopsy assay, used by biopharma for clinical-trial design and post-marketing research. Guardant Health is publicly traded (Nasdaq: GH).

Tabular
Advertisement